亚洲知识产权资讯网为知识产权业界提供一个一站式网上交易平台，协助业界发掘知识产权贸易商机，并与环球知识产权业界建立联系。无论你是知识产权拥有者正在出售您的知识产权，或是制造商需要购买技术以提高操作效能，又或是知识产权配套服务供应商，你将会从本网站发掘到有用的知识产权贸易资讯。

返回搜索结果

Mitochondria Targeting Kills Cancer Cell without Acquired Drug Resistance

技术优势: Achieves high selectivity in mitochondrial targeting of cancer cell;The first example to integrate subcellular targeting and spatial control of the assemblies of non-specific cytotoxic agents by EISA as a promising molecular process for selectively killing cancer cells;A new way for developing efficient nanomedicine without inducing acquired drug resistance.

详细技术说明: The invention introduces a novel method to target organelles by modulating the redox potential of mitochondria and ultimately serve as a therapeutic approach to cancer and other immune-deficient disease. This bioinspired system is achieved by utilizing enzyme-instructed self-assembly (EISA) to kill cancer cells that minimizes acquired drug resistance.

*Abstract: A bioinspired system which selectively generates the assemblies of redox modulators (e.g., triphenyl phosphimium (TPP)) in the pericellular space of cancer cells for uptake, allows selectively targeting the mitochondria of cancer cells. The attachment of TPP to a pair of enantiomeric, phosphorylated tetrapeptidic produces the precursors that form oligomers. The cancer cell uptake these assemblies of TPP via endocytosis, mainly via caveolar/raft dependent pathway. The assemblies of TPP-peptide conjugates will be released from lysosome, induce dysfunction of mitochondria to release cytochrome and result cell death. The conceptual system has been tested ex vivo on several cancer cell lines. The merit of this technology is the repeated stimulation of the cancers by the precursors unexpectedly sensitizes the cancer cells to the precursors. The invention is the first example of the integration of subcellular targeting and the spatial control of the assemblies of non-specific cytotoxic agents by EISA as a promising molecular process for selectively killing cancer cells without inducing acquired drug resistance. The invention also the first time to report controlling peptide self-assembly inside organelle of mitochondria of live cells, which provides new opportunity for therapeutics against cancer and some immune-deficient disease.
Download marketing summary here.

欲了解更多信息，请点击这里